Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.

What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Golden Globes host Nikki Glaser caused some controversy with her March 24 appearance on The Tonight Show after she proudly ...

Patients taking compounded weight loss drugs from online pharmacies share what it's like — and they couldn't go the ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

SELF will always acknowledge that “obesity” is both a flawed metric of health and a stigmatizing term. SELF will only talk ...

Billions of dollars in annual revenue and the health of millions of patients are at stake in a drug industry battle over who ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...